Inovio Stock Today


USD 1.90  0.11  5.47%   

Market Performance
0 of 100
Odds Of Distress
Less than 49
Inovio Pharma is selling for 1.90 as of the 28th of November 2022. This is a -5.47% down since the beginning of the trading day. The stock's open price was 2.01. Inovio Pharma has 49 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Inovio Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of January 2021 and ending today, the 28th of November 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of February 1998
Health Care
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus , cancer, and infectious diseases. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. The company has 210.39 M outstanding shares of which 45.57 M shares are currently shorted by investors with about 8.67 days to cover. More on Inovio Pharma

Moving together with Inovio Pharma

+0.67MRNAModerna Potential GrowthPairCorr
+0.69ULTAUlta Beauty Earnings Call  This WeekPairCorr
+0.67LENLennar Corp Fiscal Year End 21st of December 2022 PairCorr

Inovio Pharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Inovio Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Inovio Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Inovio Pharma generated a negative expected return over the last 90 days
Inovio Pharma has high historical volatility and very poor performance
Inovio Pharma may become a speculative penny stock
The company reported the last year's revenue of 2.11 M. Reported Net Loss for the year was (354.69 M) with loss before taxes, overhead, and interest of (247.47 M).
Inovio Pharma has about 348.13 M in cash with (196.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4.
Inovio Pharma has a frail financial position based on the latest SEC disclosures
Latest headline from INOVIO Provides an Update on Lassa Fever and MERS Programs -
CEOJoseph Kim
Thematic Ideas
(view all).
Average Analyst Recommendation
Analysts covering Inovio Pharma report their recommendations after researching Inovio Pharma's financial statements, talking to executives and customers, or listening in on Inovio Pharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Inovio Pharma. The Inovio consensus assessment is calculated by taking the average forecast from all of the analysts covering Inovio Pharma.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Inovio Pharma based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Inovio Pharma financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted225.3 M208.8 M
Significantly Up
Slightly volatile
Weighted Average Shares225.3 M208.8 M
Significantly Up
Slightly volatile
Current Liabilities70.9 M65.7 M
Significantly Up
Slightly volatile
Total Liabilities103.9 M96.3 M
Significantly Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Total Debt41.5 M33 M
Significantly Up
Slightly volatile
Asset Turnover0.00350.0034
Fairly Up
Slightly volatile
Current Assets483.8 M448.4 M
Significantly Up
Slightly volatile
Total Assets535.1 M495.9 M
Significantly Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Inovio Pharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyUndervalued
Financial Strength
Inovio Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Inovio Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inovio Pharma's financial leverage. It provides some insight into what part of Inovio Pharma's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Inovio Pharma's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Inovio Pharma deploys its capital and how much of that capital is borrowed.
Inovio Pharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 33.31 M in debt with debt to equity (D/E) ratio of 0.11, which may show that the company is not taking advantage of profits from borrowing. Inovio Pharma has a current ratio of 3.11, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Inovio Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Inovio Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Inovio Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Inovio to invest in growth at high rates of return. When we think about Inovio Pharma's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(221.39 Million)
Inovio Pharma (INO) is traded on NASDAQ Exchange in USA and employs 317 people. The company currently falls under 'Small-Cap' category with total capitalization of 435.5 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Inovio Pharma's market, we take the total number of its shares issued and multiply it by Inovio Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Inovio Pharma runs under Healthcare sector within Biotechnology industry. The entity has 210.39 M outstanding shares of which 45.57 M shares are currently shorted by investors with about 8.67 days to cover. Inovio Pharma has about 348.13 M in cash with (196.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4.
Check Inovio Pharma Probability Of Bankruptcy
Inovio Pharma secures a total of 210.39 Million outstanding shares. 30% of Inovio Pharma outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Inovio Ownership Details

Inovio Stock Price Odds Analysis

Proceeding from a normal probability distribution, the odds of Inovio Pharma jumping above the current price in 90 days from now is about 66.39%. The Inovio Pharma probability density function shows the probability of Inovio Pharma stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 2.1054. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Inovio Pharma will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Inovio Pharma is significantly underperforming DOW.
  Odds Below 1.9HorizonTargetOdds Above 1.9
33.50%90 days
Based on a normal probability distribution, the odds of Inovio Pharma to move above the current price in 90 days from now is about 66.39 (This Inovio Pharma probability density function shows the probability of Inovio Stock to fall within a particular range of prices over 90 days) .

Inovio Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Inovio Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inovio Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inovio Pharma's value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares27.4 K47 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares27.4 K98 K
View Inovio Pharma Diagnostics

Inovio Pharma Historical Income Statement

Inovio Pharma Income Statement is one of the three primary financial statements used for reporting Inovio's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Inovio Pharma revenue and expense. Inovio Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Inovio Pharma Weighted Average Shares is quite stable at the moment as compared to the past year. The company's current value of Weighted Average Shares is estimated at 225.32 Million. Weighted Average Shares Diluted is expected to rise to about 225.3 M this year, although the value of Consolidated Income will most likely fall to (311.6 M). View More Fundamentals

Inovio Stock Against Markets

Picking the right benchmark for Inovio Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Inovio Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Inovio Pharma is critical whether you are bullish or bearish towards Inovio Pharma at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inovio Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Tickers Now


Stock Tickers

Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
All  Next Launch Module

Inovio Pharma Corporate Directors

Inovio Pharma corporate directors refer to members of an Inovio Pharma board of directors. The board of directors generally takes responsibility for the Inovio Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Inovio Pharma's board members must vote for the resolution. The Inovio Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
George Bickerstaff - DirectorProfile
Lota Zoth - DirectorProfile
Simon Benito - Independent DirectorProfile
Mort Collins - Independent DirectorProfile

Invested in Inovio Pharma?

The danger of trading Inovio Pharma is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Inovio Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Inovio Pharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Inovio Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Risk vs Return Analysis. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for analysis

When running Inovio Pharma price analysis, check to measure Inovio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharma is operating at the current time. Most of Inovio Pharma's value examination focuses on studying past and present price action to predict the probability of Inovio Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inovio Pharma's price. Additionally, you may evaluate how the addition of Inovio Pharma to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is Inovio Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharma. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
501.5 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Inovio Pharma is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharma's value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharma's market value can be influenced by many factors that don't directly affect Inovio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Inovio Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.